Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
INBRX-106 - Hexavalent OX40 agonist antibody Phase 2 Results Expected
INBRX-106 - Hexavalent OX40 agonist antibody • Solid Tumor
Target Indication
Solid Tumor
Clinical Trial
Last updated: 12/4/2025
INBX
Inhibrx Biosciences, Inc.
